SCHEMBL2275544

SCHEMBL2275544

O=C(Nc1cc(Oc2ccccc2)ccc1C(=O)O)c1cccc(-c2ccccc2)c1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FABP1 P07148 2/20 0.61
SUCNR1 Q9BXA5 1/20 0.59
MCL1 Q07820 2/20 0.59
GALK1 P51570 1/20 0.59
CASP6 P55212 1/20 0.59
PLEC Q15149 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
SERPINE1 P05121 2/20 0.57
BCL2L1 Q07817 1/20 0.56
ACLY P53396 1/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
PYGM P11217 1/20 0.55
PKM P14618 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270621 0.90 GALK1 (0.68) MCL1GALK1CASP6PLECTDP1
SCHEMBL2271588 0.90 SERPINE1 (0.64) MCL1GALK1CASP6PLECTDP1
SCHEMBL2272033 0.88 ACLY (0.62) MCL1GALK1CASP6PLECTDP1
SCHEMBL2275060 0.88 AKR1C4 (0.59) SERPINE1MEN1KMT2ANPC1RAB9A
SCHEMBL2273436 0.86 PYGM (0.70) MCL1GALK1CASP6PLECTDP1
SCHEMBL2269525 0.86 GRIK1 (0.66) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL2273349 0.86 MEN1 (0.61) MEN1KMT2ANPC1RAB9APYGM
SCHEMBL2271177 0.86 PYGM (0.72) FABP1MEN1KMT2ANPC1RAB9A
SCHEMBL2270287 0.86 PYGM (0.70) SERPINE1ACLYMEN1KMT2ANPC1
SCHEMBL2274830 0.86 MEN1 (0.54) SERPINE1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 FABP1 4190/4885SUCNR1 637/4885MCL1 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.